Title
Ciliary Neurotrophic Factor (CNTF) Safety Trial in Patients With Macular Telangiectasia (Mactel)
A Phase 1 Multicenter Open Label Safety and Tolerability Clinical Trial of Ciliary Neurotrophic Factor (CNTF) in Patients With Macular Telangiectasia Type 2 (Mactel)
Phase
Phase 1Lead Sponsor
Neurotech PharmaceuticalsStudy Type
InterventionalStatus
Completed No Results PostedIndication/Condition
Idiopathic Juxtafoveal TelangiectasiaIntervention/Treatment
ciliary neurotrophic factor ...Study Participants
7This study is a phase 1, open label, non-randomized, multi-center, pilot study to evaluate the safety and tolerability of NT-501 implants in 5-7 study participants with Mactel.
Protocol for Extended Follow-up of a Phase 1 Multicenter Open Label Safety and Tolerability Clinical Trial of Ciliary Neurotrophic Factor (CNTF) in Patients with Macular Telangiectasia Type 2 (MacTel)
Ciliary neurotrophic factor (CNTF) implant
Biological/Vaccine:NT-501 implant
Inclusion Criteria: The participant must be offered sufficient opportunity to review the informed consent form, agree to the form's contents and sign the protocol's informed consent; The participant must have bilateral MacTel; Women of childbearing potential and all men must agree to use an effective form of birth control during the study; Participant must be medically able to undergo ophthalmic surgery for ECT implant; The participant's best-corrected visual acuity 64 letters or better (20/50 or better) in the study eye; Exclusion Criteria: Participant is < 21 years of age; Participant is medically unable to comply with study procedures or follow- up visits; Participant has evidence of ocular disease other than MacTel that may confound the outcome of the study (e.g., diabetic retinopathy with manifest macular edema, uveitis, etc.); Participant has a chronic requirement (e.g., ≥ 4 weeks at a time) for ocular medications and/or has a diagnosed disease, that in the judgment of the examining physician, may be vision threatening or may affect the primary outcome (artificial tears are permitted); Participant has evidence of subretinal neovascularization in either eye; Participant has evidence of central serous chorio-retinopathy (CSR) in either eye; Participant has evidence of pathologic myopia in either eye; Participant has had a vitrectomy, penetrating keratoplasty, trabeculectomy or trabeculoplasty;